Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection

Medical Mycology

Volumn 47, Issue 7, 2009, Pages 753-758

  Schaller, Martin ^a   Borelli, Claudia ^b   Berger, Ursula ^c   Walker, Birgit ^a   Schmidt, Sybille ^a   Weindl, Günther ^a   Jäckel, Andreas ^d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c BIELEFELD UNIVERSITY   (Germany)

^d Galderma Laboratorium GmbH   (Germany)

Author keywords

Amorolfi ne; Bifonazole; Ciclopiroxolamine; In vitro; Nail infection; Onychomycosis; Trichophyton rubrum

Indexed keywords

AMOROLFINE; BIFONAZOLE; CICLOPIROXOLAMINE; PAINT;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FUNGICIDAL ACTIVITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ONYCHOMYCOSIS; TRICHOPHYTON RUBRUM;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; HUMANS; IMIDAZOLES; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MORPHOLINES; ONYCHOMYCOSIS; PYRIDONES; TRICHOPHYTON;

TRICHOPHYTON RUBRUM;

EID: 71049192432     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780802577892     Document Type: Article

References (23)

1. Effendy I, Lecha M, Feuilhade de Chauvin M, Di Chiacchio N, Baran R. Epidemiology and clinical classifi cation of onychomycosis. J Eur Acad Dermatol Venereol 2005; 19 ( Suppl. 1 ): 8-12.
2. Gupta AK, Ryder JE, Skinner AR. Treatment of onychomycosis: pros and cons of antifungal agents. J Cutan Med Surg 2004; 8: 25-30
3. Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran R (2005) Treatment options - development of consensus guidelines. J Eur Acad Dermatol Venereol 2005; 19 ( Suppl. 1): 25-33.
4. Flagothier C, Pierard-Franchimont C, Pierard GE. New insights into the effect of amorolfi ne nail lacquer. Mycoses 2005; 48: 91-94.
5. Monti D, Saccomani L, Chetoni P, et al. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, watersoluble nail lacquer. Drug Dev Ind Pharm 2005; 31: 11-17.
6. Gupta AK, Baran R. Ciclopirox nail lacquer solution 8% in the 21st century. J Am Acad Dermatol 2000; 43: 96-102.
7. Bonifaz A, Guzman A, Garcia C, Sosa J, Saul A. Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis. Int J Dermatol 1995; 34: 500-503.
8. Osborne CS, Leitner I, Favre B, Ryder NS. Antifungal drug response in an in vitro model of dermatophyte nail infection. Med Mycol 2004; 42: 159-163.
9. Summary of product characteristics (Fachinformation) Batrafen Nail lacquer (Nagel Batrafen) ; Chapter 5 Pharmacodynamic properties ; Status Aug 2007.
10. Li RY, Wan Z, Wang AP, et al. In vitro susceptibility testing of amorolfine in pathogenic fungi isolated from dermatomycosis patients in China. Mycoses 2004; 47: 402-406.
11. Jessup CJ, Warner J, Isham N, Hasan I, Ghannoum MA. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol 2000; 38: 341-344.
12. Plempel M, Regel E, Buchel KH. Antimycotic efficacy of bifonazole in vitro and in vivo. Arzneimittelforschung 1983; 33: 517-524.
13. Feuilhade De Chauvin M, Marie M-D,Claire L. I n vitro antifungal activity of amorolfi ne, bifonazole, ciclopirox and terbinafi ne against Trichophyton rubrum and Trichophyton mentagrophytesvar. interdigitale. J Eur Acad Dermatol Venereol 2003 (Suppl. 3 ); 17: S319.
14. Favre B, Hofbauer B, Hildering KS, Ryder NS. Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermato phytes by using a microdilution assay. J Clin Microbiol 2003; 41: 4817-4819.
15. Santos DH, Hamdan JS. In vitro antifungal oral drug and drugcombination activity against onychomycosis causative dermatophytes. Med Mycol 2006; 44: 357-362.
16. Hui X, Wester RC, Barbadillo S, et al. Ciclopirox delivery into the human nail plate. J Pharm Sci 2004; 93: 2545-2548.
17. Polak A. Kinetics of amorolfine in human nails. Mycoses 1993; 36: 101-103
18. Mensing H, Polak-Wyss A, Splanemann V. Determination of the subungual antifungal activity of amorolfi ne after 1 month's treatment in patients with onychomycosis: comparison of two nail lacquer formulations. Clin Exp Dermatol 1992; 17 ( Suppl. 1 ): 29-32.
19. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000; 43 ( Suppl. 4 ): 57-69.
20. Tatsumi Y, Yokoo M, Senda H, Kakehi K. Therapeutic effi cacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. Antimicrob Agents Chemother 2002; 46: 3797-37801.
21. Nakashima T, Nozawa A, Ito T, Majima T. Experimental tinea unguium model to assess topical antifungal agents using the infected human nail with dermatophyte in vitro. J Infect Chemother 2002; 8: 331-335.
22. Halmy K. Experience with nail lacquers containing amorolfi ne 5% and ciclopirox 8% in patients with onychomycosis. J Eur Acad Dermatol Venereol 2004; 18 ( Suppl. 1 ): 242.
23. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005; 19: 21-29